GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Biote Corp (NAS:BTMD) » Definitions » Degree of Financial Leverage

Biote (BTMD) Degree of Financial Leverage : 0.58 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biote Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Biote's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was 0.58. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Biote's Degree of Financial Leverage or its related term are showing as below:

BTMD's Degree of Financial Leverage is ranked better than
73.36% of 642 companies
in the Healthcare Providers & Services industry
Industry Median: 1.02 vs BTMD: 0.58

Biote Degree of Financial Leverage Historical Data

The historical data trend for Biote's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biote Degree of Financial Leverage Chart

Biote Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
- 1.04 1.35 0.86 -5.41

Biote Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 0.28 0.24 -5.41 0.58

Competitive Comparison of Biote's Degree of Financial Leverage

For the Medical Care Facilities subindustry, Biote's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biote's Degree of Financial Leverage Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Biote's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Biote's Degree of Financial Leverage falls into.



Biote Degree of Financial Leverage Calculation

Biote's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( 0.11 (Mar. 2024) / -0.548 (Mar. 2023) - 1 )/( 24.632 (Mar. 2024) / -23.085 (Mar. 2023) - 1 )
=-1.2007/-2.067
=0.58***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Biote  (NAS:BTMD) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Biote Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Biote's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Biote (BTMD) Business Description

Traded in Other Exchanges
N/A
Address
1875 West Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038
Biote Corp is engaged in bioidentical hormone replacement optimization platform and complementary nutraceutical business. The company offers end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support.
Executives
Mary Elizabeth Conlon officer: General Counsel C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Anil K Shrivastava 10 percent owner 200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Michael David Braner 10 percent owner 200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Daniel M. Friedberg 10 percent owner C/O SAGARD CAPITAL, 325 GREENWICH AVENUE, GREENWICH CT 06830
325 Capital Llc 10 percent owner 757 THIRD AVENUE, 20TH FLOOR, NEW YORK NY 10017
Mary Joan Puncochar officer: Chief Commercial Officer C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Roystone Capital Holdings Llc 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Roystone Capital Management Lp 10 percent owner 780 THIRD AVENUE, 41ST FLOOR, NEW YORK NY 10017
Samar Jagat Kamdar officer: Chief Financial Officer 7042 CORONADO AVE., DALLAS TX 75214
Marc D Beer director C/O AEGERION PHARMACEUTICALS, 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Guines Llc 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Richard R Barrera 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Debra L Morris director 11620 WILSHIRE BOULEVARD, SUITE 1000, LOS ANGELES CA 90025
Andrew R Heyer director, officer: President and Director 501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Teresa Sue Weber director, officer: Chief Executive Officer C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038

Biote (BTMD) Headlines

From GuruFocus

Biote to Participate at Upcoming Investor Conferences

By Business Wire Business Wire 05-31-2023

Biote Reports Third Quarter Financial Results

By Business Wire Business Wire 11-08-2022

Biote Reports Second Quarter 2023 Financial Results

By Business Wire 08-10-2023

Biote to Purchase Asteria Health

By Business Wire 01-17-2024

Biote Appoints Mary J. Puncochar as Chief Commercial Officer

By Business Wire Business Wire 05-30-2023